Article Information
History
- March 10, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Uri Greenbaum*,1,
- Kimberly Klein*,2,
- Fernando Martinez2,
- Juhee Song3,
- Peter F. Thall3,
- Jeremy L. Ramdial1,
- Cristina Knape1,
- Fleur M. Aung2,
- Jamie Scroggins2,
- Adriana Knopfelmacher2,
- Victor Mulanovich4,
- Jovan Borjan5,
- Javier Adachi4,
- Mayoora Muthu6,
- Cerena Leung6,
- Mayrin Correa Medina2,
- Richard Champlin1,
- Amanda Olson1,
- Amin Alousi1,
- Katayoun Rezvani1 and
- Elizabeth J. Shpall#,1
- 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 2Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 4Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 5Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 6Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
- ↵#Correspondence: Elizabeth J. Shpall, MD, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, 713-745-2161, eshpall{at}mdanderson.org
↵* Both authors contributed equally to the manuscript
Posted March 10, 2021.
High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients
